Sivextro is approved for the treatment of acute bacterial skin infections, including those caused by methicillin-resistant Staphylococcus aureus.
The oral treatment option of the drug has been available since June, according to Rob Perez, president and COO of Cubist, but the I.V. version is newly available. “We believe the features and utility of Sivextro offers physicians an effective option to treat acute bacterial skin and skin structure infections in a number of real-life patient settings — from the hospital to the home,” he said in a news release.
More articles on MRSA:
10 recent stories, studies on MRSA
Changes in MRSA Treatment: 4 Trends
Methicillin-Susceptible S. aureus Strains a Concern in Neonatal Care Settings
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
